1. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 1985;314:53–57. [PubMed] 2. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside–KLH conjugate vaccines. Immunol Rev. 1995;145:147–166. [PubMed] 3. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309–5318. [PubMed] 4. Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 1990;50:4308–4314. [PubMed] 5. Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol. 2005;83:418–428. [PubMed] 6. Ouerfelli O, Warren JD, Wilson RM, Danishefsky SJ. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities. Expert Rev Vaccines. 2005;4:677–685. [PubMed] 7. Helling F, et al. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 1994;54:197–203. [PubMed] 8. Helling F, et al. GM2–KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995;55:2783–2788. [PubMed] 9. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991;146:431–437. [PubMed] 10. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother. 1996;43:152–157. [PubMed] 11. Livingston PO, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–1044. [PubMed] 12. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emph Tumor Immunol. 1996;19:59–68. [PubMed] 13. Slovin SF, et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA. 1999;96:5710–5715. [PubMed] 14. Ragupathi G, et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer. 2000;85:659–666. [PubMed] 15. Ragupathi G, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214–5220. [PubMed] 16. Slovin SF, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 2003;21:4292–4298. [PubMed] 17. Krug LM, et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res. 2004;10:6094–6100. [PubMed] 18. Slovin SF, et al. Thomsen–Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother. 2005;54:694–702. [PubMed] 19. Ragupathi G, Gathuru J, Livingston P. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res. 2005;123:157–180. [PubMed] 20. Livingston PO, Ragupathi G. Cancer vaccines targeting carbohydrate antigens. Hum Vaccin. 2006;2:137–143. [PubMed]
21. Toyokuni T, Singhal AK. Synthetic carbohydrate vaccines based on tumour-associated antigens. Chem Soc Rev. 1995:231–242.
22. Danishefsky SJ, Allen JR. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew Chem Int Ed. 2000;39:836–863. [PubMed] 23. Brocke C, Kunz H. Synthesis of tumor-associated glycopeptide antigens. Bioorg Med Chem. 2002;10:3085–3112. [PubMed] 24. Buskas T, Ingale S, Boons GJ. Glycopeptides as versatile tools for glycobiology. Glycobiology. 2006;16:113R–136R. [PubMed]
25. Paulsen H. Advances in stereoselective chemical syntheses of complex oligosaccharides. Angew Chem Int Ed Engl. 1982;21:155–224.
26. Sinay P. Recent advances in glycosylation reactions. Pure Appl Chem. 1991;63:519–528.
27. Toshima K, Tatsuta K. Recent progress in O-glycosylation methods and its application to natural products synthesis. Chem Rev. 1993;93:1503–1531.
28. Schmidt RR, Kinzy W. Anomeric-oxygen activation for glycoside synthesis: the trichloroacetimidate method. Adv Carbohydr Chem Biochem. 1994;50:21–123. [PubMed] 29. Garegg PJ. Thioglycosides as glycosyl donors in oligosaccharide synthesis. Adv Carbohydr Chem Biochem. 1997;52:179–205. [PubMed]
30. Davis BG. Recent developments in oligosaccharide synthesis. J Chem Soc Perkin Trans. 2000;1:2137–2160.
31. Hanessian S, Lou B. Stereocontrolled glycosyl transfer reactions with unprotected glycosyl donors. Chem Rev. 2000;100:4443–4464. [PubMed] 32. Nicolaou KC, Mitchell HJ. Adventures in carbohydrate chemistry: new synthetic technologies, chemical synthesis, molecular design, and chemical biology. Angew Chem Int Ed. 2001;40:1576–1624. [PubMed]
33. Danishefsky SJ, Bilodeau MT. Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. Angew Chem Int Ed. 1996;35:1380–1419.
34. Di Bussolo V, Kim YJ, Gin DY. Direct oxidative glycosylations with glycal donors. J Am Chem Soc. 1998;120:13515–13516.
35. Shi L, Kim YJ, Gin DY. C2-acyloxyglycosylation with glycal donors. J Am Chem Soc. 2001;123:6939–6940. [PubMed]
36. Lemieux RU, Ratcliffe RM. The azidonitration of tri-O-acetyl-d-galactal. Can J Chem. 1979;57:1244–1251.
37. Kan C, et al. Photo amidoglycosylation of an allal azidoformate. Synthesis of β-2-amido allopyranosides. Org Lett. 2001;3:381–384. [PubMed] 38. Di Bussolo V, Liu J, Huffman LG, Gin DY. Acetamidoglycosylation with glycal donors: a one-pot glycosidic coupling with direct installation of the natural C(2)-N-acetylamino functionality. Angew Chem Int Ed. 2000;39:204–207. [PubMed] 39. Kannagi R, et al. New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J Biol Chem. 1983;258:8934–8942. [PubMed] 40. Bremer EG, et al. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem. 1984;259:14773–14777. [PubMed] 41. Hakomori S, Zhang Y. Glycosphingolipid antigens and cancer therapy. Chem Biol. 1997;4:97–104. [PubMed]
42. Bilodeau MT, et al. Total synthesis of a human breast tumor associated antigen. J Am Chem Soc. 1995;117:7840–7841.
43. Park TK, et al. Total synthesis and proof of structure of a human breast tumor (globo-H) antigen. J Am Chem Soc. 1996;118:11488–11500.
44. Zhu T, Boons GJ. A two-directional and highly convergent approach for the synthesis of the tumor-associated antigen globo-H. Angew Chem Int Ed. 1999;38:3495–3497. [PubMed]
45. Douglas NL, Ley SV, Lucking U, Warriner SL. Tuning glycoside reactivity: new tool for efficient oligosaccharide synthesis. J Chem Soc Perkin Trans. 1998;1:51–66.
46. Burkhart F, Zhang Z, Wacowich-Sgarbi S, Wong CH. Synthesis of the Globo H hexasaccharide using the programmable reactivity-based one-pot strategy. Angew Chem Int Ed. 2001;40:1274–1277. [PubMed]
47. Zhang Z, et al. Programmable one-pot oligosaccharide synthesis. J Am Chem Soc. 1999;121:734–753.
48. Huang CY, et al. Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc Natl Acad Sci USA. 2006;103:15–20. [PubMed]
49. Lassaletta J, Schmidt RR. Glycosyl imidates. Part 75. Synthesis of the hexasaccharide moiety of globo H (human breast cancer) antigen. Liebigs Ann. 1996:1417–1423.
50. Bosse F, Marcaurelle LA, Seeberger PH. Linear synthesis of the tumor-associated carbohydrate antigens Globo-H, SSEA-3, and Gb3. J Org Chem. 2002;67:6659–6670. [PubMed] 51. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 1989;52:257–331. [PubMed] 52. Boons GJ, Demchenko AV. Recent advances in O-sialylation. Chem Rev. 2000;100:4539–4565. [PubMed] 53. Haberman JM, Gin DY. Dehydrative sialylation with C2-hemiketal sialyl donors. Org Lett. 2003;5:2539–2541. [PubMed]
54. Castro-Palomino JC, et al. Efficient synthesis of ganglioside GM2 for use in cancer vaccines. Angew Chem Int Ed. 1997;36:1998–2001.
55. Gordon JE, Turrell GC. Observations on N-methylacetonitrilium and N-phenylbenzonitrilium hexachloroantimonates. J Org Chem. 1959;24:269–271.
56. Schmidt RR, Ruecker E. Stereoselective glycosidations of uronic acids. Tetrahedron Lett. 1980;21:1421–1424.
57. Hasegawa A, et al. Synthetic studies on sialoglycoconjugates 25: reactivity of glycosyl promoters in α-glycosylation of N-acetylneuraminic acid with the primary and secondary hydroxyl groups in the suitably protected galactose and lactose derivatives. J Carbohydr Chem. 1991;10:493–498.
58. De Meo C, Demchenko AV, Boons GJ. A stereoselective approach for the synthesis of α-sialosides. J Org Chem. 2001;66:5490–5497. [PubMed] 59. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature Rev Cancer. 2004;4:45–60. [PubMed] 60. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci. 1992;17:359–363. [PubMed] 61. Müller S, Hanisch FG. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem. 2002;277:26103–26112. [PubMed] 62. Marcos NT, et al. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. J Histochem Cytochem. 2003;51:761–771. [PubMed]
63. Banoub J, Boullanger P, Lafont D. Synthesis of oligosaccharides of 2-amino-2-deoxy sugars. Chem Rev. 1992;92:1167–1195.
64. Liebe B, Kunz H. Solid-phase synthesis of a tumor-associated sialyl-TN antigen glycopeptide with a partial sequence of the ‘tandem repeat’ of the MUC-1 mucin. Angew Chem Int Ed. 1997;36:618–621.
65. Kunz H, Birnbach S. Synthesis of tumor associated TN- and T-antigen type O-glycopeptides and their conjugation to bovine serum albumin. Angew Chem Int Ed. 1986;98:360–362.
66. Sames D, Chen XT, Danishefsky SJ. Convergent total synthesis of a tumour-associated mucin motif. Nature. 1997;389:587–591. [PubMed]
67. Paulsen H, Rauwald W, Weichert U. Building units of oligosaccharides. LXXXVI. Glycosidation of oligosaccharide thioglycosides to O-glycoprotein segments. Liebigs Ann. 1988:75–86.
68. George SK, et al. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides. J Am Chem Soc. 2001;123:11117–11125. [PubMed] 69. Svarovsky SA, Barchi JJ. Highly efficient preparation of tumor antigen-containing glycopeptide building blocks from novel pentenyl glycosides. Carbohydr Res. 2003;338:1925–1935. [PubMed] 70. Rademann J, Schmidt RR. Solid-phase synthesis of a glycosylated hexapeptide of human sialophorin, using the trichloroacetimidate method. Carbohydr Res. 1995;269:217–225. [PubMed] 71. Paulsen H, Peters S, Bielfeldt T, Meldal M, Bock K. Synthesis of the glycosyl amino acids Nα-Fmoc-Ser[Ac4-β-d-Gal p-(1→3)-Ac2-α-d-GalN3p]-OPfp and Nα-Fmoc-Thr[Ac4-β-d-Gal p-(1→3)-Ac2-α-d-GalN3p]-OPfp and the application in the solid-phase peptide synthesis of multiply glycosylated mucin peptides with Tn and T antigenic structures. Carbohydr Res. 1995;268:17–34. [PubMed] 72. Nakahara Y, Nakahara Y, Ogawa T. Solid-phase synthesis of an O-linked glycopeptide based on a benzyl-protected glycan approach. Carbohydr Res. 1996;292:71–81. [PubMed]
73. Winterfeld GA, Khodair AI, Schmidt RR. O-glycosyl amino acids by 2-nitrogalactal concatenation — synthesis of a mucin-type O-glycan. Eur J Org Chem. 2003:1009–1021.
74. Elofsson M, Salvador LA, Kihlberg J. Preparation of Tn and sialyl Tn building blocks used in Fmoc solid-phase synthesis of glycopeptide fragments from HIV gp120. Tetrahedron. 1997;53:369–390.
75. Seitz O, Kunz H. A novel allylic anchor for solid-phase synthesis — synthesis of protected and unprotected O-glycosylated mucin-type glycopeptides. Angew Chem Int Ed. 1995;34:803–805.
76. Dziadek S, Hobel A, Schmitt E, Kunz H. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Angew Chem Int Ed. 2005;44:7630–7635. [PubMed] 77. Dziadek S, Brocke C, Kunz H. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4. Chem Eur J. 2004;10:4150–4162. [PubMed] 78. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carr Syst. 1996;13:1–55. [PubMed] 79. Jacobsen NE, et al. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr Res. 1996;280:1–14. [PubMed]
80. Zhu X, Yu B, Hui Y, Schmidt RR. Synthesis of the trisaccharide and tetrasaccharide moieties of the potent immunoadjuvant QS-21. Eur J Org Chem. 2004:965–973.
81. Nukada T, Berces A, Zgierski MZ, Whitfield DM. Exploring the mechanism of neighboring group assisted glycosylation reactions. J Am Chem Soc. 1998;120:13291–13295.
82. Kim YJ, et al. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc. 2006;128:11906–11915. [PMC free article] [PubMed]
83. Garcia BA, Gin DY. Dehydrative glycosylation with activated diphenyl sulfonium reagents. Scope, mode of C(1)-hemiacetal activation, and detection of reactive glycosyl intermediates. J Am Chem Soc. 2000;122:4269–4279.
84. Ishihara K, Yamamoto H. Arylboron compounds as acid catalysts in organic synthetic transformations. Eur J Org Chem. 1999:527–538.
85. Nores GA, Dohi T, Taniguchi M, Hakomori S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol. 1987;139:3171–3176. [PubMed] 86. Zhang S, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer. 1997;73:50–56. [PubMed] 87. Ragupathi G, et al. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J Am Chem Soc. 2006;128:2715–2725. [PubMed] 88. Lo-Man R, et al. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 2004;64:4987–4994. [PubMed] 89. Grigalevicius S, et al. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug Chem. 2005;16:1149–1159. [PubMed]
90. Svarovsky SA, Szekely Z, Barchi JJ. Synthesis of gold nanoparticles bearing the Thomsen–Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen. Tetrahedron Asymmetry. 2005;16:587–598.
91. Jiang ZH, Koganty RR. Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem. 2003;10:1423–1439. [PubMed] 92. Buskas T, Ingale S, Boons GJ. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew Chem Int Ed. 2005;44:5985–5988. [PubMed] 93. Marciani DJ, et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000;18:3141–3151. [PubMed] 94. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934–943. [PubMed]